^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | cirtuvivint (SM08502) (pan-CLK inhibitor, DYRK inhib) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 6401: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt and cyclin D-CDK4/6-RB pathway inhibition in hormone-receptor-positive (HR+) breast cancer models
Published date:
05/15/2020
Excerpt:
Together, these data suggest that SM08502 has potential antitumor activity in HR+ BC and may provide clinical benefit as a single agent or combined with standard therapy.
DOI:
10.1158/1538-7445.AM2020-6401
